Publication:
Investigation of the effects of rapamycin on the mTOR pathway and apoptosis in metastatic and non-metastatic human breast cancer cell lines

dc.contributor.authorEkizceli, Gülçin
dc.contributor.authorUluer, Elgin T.
dc.contributor.authorİnan, Sevinç
dc.contributor.buuauthorEkizceli, Gülçin
dc.contributor.buuauthorUluer, Elgin T.
dc.contributor.buuauthorİnan, Sevinç
dc.contributor.departmentSağlık Bilimleri Enstitüsü
dc.contributor.departmentHistoloji ve Embriyoloji Ana Bilim Dalı
dc.contributor.orcid0000-0001-9513-5706
dc.contributor.researcheridAAZ-2915-2020
dc.contributor.researcheridAAP-3523-2020
dc.contributor.researcheridAAN-2767-2021
dc.contributor.researcheridFAZ-8671-2022
dc.date.accessioned2024-07-02T05:53:23Z
dc.date.available2024-07-02T05:53:23Z
dc.date.issued2020-01-01
dc.description.abstractAIM: The aim of this study was to analyze the effects of rapamycin treatment on apoptosis via mTOR pathway in metastatic and non-metastatic human breast cancer cell lines by immunohistochemical and TUNEL analysis.METHOD: MCF-7 and MDA-MB 231 cell lines were incubated under standard conditions forming Rapamycin and control groups. In immunohistochemical evaluation; mTOR pathway was evaluated with anti-IGF1, anti-PI3K, anti-pAKT1/2/3, anti-mTORC1, anti-mTORC2 and anti-ERK1 antibodies. The effect of apoptosis was also confirmed by TUNEL method.RESULTS: In this study, activation of PI3K/AKT/mTOR and related molecular pathways in the MDA-MB 231 and MCF-7 breast cancer cell line was evaluated and it was observed that these pathways could play a key role in cancer development. Increased apoptotic cells were observed in mTORC1 inhibition by Rapamycin administration.CONCLUSION: Targeting the mTOR pathway in breast cancer treatment may be a treatment option. In addition, the demonstration and confirmation of increased apoptosis in Rapamycin treated groups suggested that Rapamycin, an inhibitor of mTOR, is promising in the treatment of breast cancer (Tab. 2, Fig. 3, Ref. 66). Text in PDF www.elis.sk.
dc.identifier.doi10.4149/BLL_2020_049
dc.identifier.endpage315
dc.identifier.issn0006-9248
dc.identifier.issue4
dc.identifier.scopus2-s2.0-85087045196
dc.identifier.startpage308
dc.identifier.urihttps://doi.org/10.4149/BLL_2020_049
dc.identifier.urihttp://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=6691&category_id=158&option=com_virtuemart&vmcchk=1&Itemid=1
dc.identifier.urihttps://hdl.handle.net/11452/42679
dc.identifier.volume121
dc.identifier.wos000530579700011
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherAepress
dc.relation.journalBratislava Medical Journal-Bratislavske Lekarske Listy
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectEstrogen-receptor
dc.subjectMammalian protein
dc.subjectActivation
dc.subjectInhibitors
dc.subjectComplex
dc.subjectTarget
dc.subjectPhosphorylation
dc.subjectPi3k/akt/mtor
dc.subjectExpression
dc.subjectAlpha
dc.subjectMda-mb 231
dc.subjectMcf-7
dc.subjectBreast cancer
dc.subjectmTOR
dc.subjectRapamycin
dc.subjectGeneral & internal medicine
dc.titleInvestigation of the effects of rapamycin on the mTOR pathway and apoptosis in metastatic and non-metastatic human breast cancer cell lines
dc.typeArticle
dspace.entity.typePublication
local.contributor.departmentSağlık Bilimleri Enstitüsü/Histoloji ve Embriyoloji Ana Bilim Dalı
local.indexed.atWOS
local.indexed.atScopus

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Ekizceli_vd_2020.pdf
Size:
566.5 KB
Format:
Adobe Portable Document Format